Brenmiller Energy appoints Harel Gadot as independent director to board

Brenmiller Energy Ltd . (NASDAQ:BNRG) announced Thursday the appointment of Harel Gadot as an independent director to its board, effective immediately. The decision was made by the company’s board of directors and fills a vacancy that will be created when the term of current board member Chen Franco-Yehuda expires on August 25, 2025.

According to the press release statement, Mr. Gadot, age 53, brings over 25 years of leadership experience in the healthcare sector across the United States, Europe, and Israel. He is the founder, chief executive officer, president, and chairman of Microbot Medical (TASE:BLWV) Inc. (NASDAQ:MBOT), which he led through its NASDAQ listing in 2016. Under his leadership, MBOT has achieved remarkable market performance, with a 195% year-to-date return and maintains a strong financial health score according to InvestingPro analysis. Gadot also serves as founder and chairman of MEDX Ventures Group and MEDX Xelerator LP, a government-supported medical device incubator in Israel, established in partnership with Boston Scientific Corporation (NYSE:BSX) and Sheba Medical Center. While MBOT currently operates at a pre-profit stage with negative EBITDA, the company maintains exceptional liquidity with a current ratio of 12.06, demonstrating strong financial management. Unlock more insights and discover 8 additional key metrics with InvestingPro.

Previously, Gadot founded XACT Robotics in 2013 and served as its executive chairman until 2023. He also served on the board of ConTIPI Ltd. until its acquisition by Kimberly Clark (NASDAQ:KMB) Corporation. Earlier in his career, Gadot held senior marketing positions at Johnson & Johnson in the United States, France, and Israel.

Gadot holds a Bachelor of Science from Siena College, a Master of Business Administration from the University of Manchester, and an executive degree in finance from Harvard Business School.

The company stated that Gadot has no direct or indirect material interest in any transaction required to be disclosed under Item 404(a) of Regulation S-K. There are no arrangements or understandings between Gadot and any other persons regarding his appointment to the board.

Additionally, Brenmiller Energy noted that it is refiling its proxy statement for its upcoming annual and special general meeting of shareholders, scheduled for September 25, 2025, to correct a typographical error. No other changes have been made to the proxy statement.

All information is based on a press release statement and the company’s filing with the U.S. Securities and Exchange Commission.

In other recent news, Microbot Medical has been active with several significant developments. The company reported raising $3 million through the exercise of Series F and Series G preferred investment options, as detailed in a recent SEC filing. Additionally, Microbot Medical has been granted a new patent by the United States Patent and Trademark Office for its LIBERTY endovascular robotic system, which has helped maintain its Buy rating and $9.00 price target at H.C. Wainwright. In China, the company expanded its intellectual property portfolio with a patent for robotic manipulation of surgical tool handles.

Further corporate changes include the expansion of authorized shares following a stockholder vote, doubling the authorized common stock from 60 million to 120 million shares. In leadership news, Microbot Medical appointed Christina Bailey as its new Vice President of Sales. Bailey, a former U.S. Olympian, brings 20 years of medical device sales experience to the role. These recent developments highlight Microbot Medical’s ongoing efforts in innovation and strategic growth.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.